DY
BIO icon

Dowling & Yahnke’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dowling & Yahnke’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-681
Closed -$397K – 338
2020
Q4 		$397K Sell
681
-74
-10% -$42.1K 0.03% 264
2020
Q3 		$389K Buy
755
+25
+3% +$12.7K 0.03% 252
2020
Q2 		$330K Sell
730
-6
-0.8% -$2.65K 0.03% 260
2020
Q1 		$258K Sell
736
-20
-3% -$7.35K 0.02% 264
2019
Q4 		$280K Sell
756
-50
-6% -$17.6K 0.02% 273
2019
Q3 		$268K Buy
806
+20
+3% +$6.52K 0.02% 272
2019
Q2 		$246K Buy
+786
New +$235K 0.02% 269
2018
Q4 		– Sell
-659
Closed -$206K – 264
2018
Q3 		$206K Sell
659
-268
-29% -$83.2K 0.02% 275
2018
Q2 		$267K Hold
927
– – 0.02% 254
2018
Q1 		$232K Hold
927
– – 0.02% 267
2017
Q4 		$221K Sell
927
-83
-8% -$20.1K 0.02% 276
2017
Q3 		$224K Hold
1,010
– – 0.02% 267
2017
Q2 		$229K Hold
1,010
– – 0.02% 261
2017
Q1 		$201K Buy
+1,010
New +$195K 0.02% 268

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Dowling & Yahnke's BIO Position: Q1 2021 in Review

Dowling & Yahnke sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 681 shares — an estimated $397K sold.

Dowling & Yahnke first reported a position in BIO in Q1 2017 and held it in 14 quarters. The position peaked at $397K in Q4 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Dowling & Yahnke reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
  • Dowling & Yahnke sold 681 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $397K.
  • Dowling & Yahnke first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 14 quarters.
  • Dowling & Yahnke's Bio-Rad Laboratories Class A position peaked at $397K in Q4 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Dowling & Yahnke's 13F filing for Q1 2021, filed 29 Apr 2021.